Rare Disease Resource Library

Medical Professionals, Researchers, RDCA-DAP, Research & Drug Development, Collection, Research,

October 17, 2022

Accelerating Rare Disease Drug Development: RDCA-DAP – Shortening the Timeline for Developing New Treatments for Rare Diseases

Medical Professionals, Researchers, RDCA-DAP, Research & Drug Development, Collection, Research,

Accelerating Rare Disease Drug Development: Rare Disease Challenges in Each Step of the Drug Development Process.

Medical Professionals, Researchers, RDCA-DAP, Research & Drug Development, Collection, Research,

Accelerating Rare Disease Drug Development: The Drug Development Process

Advocates, Medical Professionals, Researchers, Advocacy, RDCA-DAP, Research & Drug Development, Educational Video, Research,

What You Need to Know About the Rare Disease Cures Accelerator-Data and Analytics Platform

Advocates, Medical Professionals, Researchers, Advocacy, RDCA-DAP, Research & Drug Development, Infographic, PDF, Research,

RDCA-DAP® Data Collaboration Center Graphic

Advocates, Medical Professionals, Researchers, RDCA-DAP, Research & Drug Development, Educational Video, Webinar, Research,

Sharing Data With RDCA-DAP: Your Questions Answered

Advocates, Medical Professionals, Patient & Caregiver, Patient Organizations, RDCA-DAP, Research & Drug Development, Understanding Rare Disease, Educational Video, Education, Policy,

What is Patient Focused Drug Development (PFDD)?

Forming a Foundation, Research Ready, Research & Registries, Medical Professionals, Patient & Caregiver, Researchers, Research & Drug Development, Educational Video, Webinar, Research,

October 14, 2022

Natural History Studies and Patient Registries

Medical Professionals, Patient & Caregiver, Patient Organizations, Research & Drug Development, Externally-Led Patient-Focused Drug Development, Membership, Research,

October 4, 2022

Voice of the Patient Report: Post-Transplant Lymphoproliferative Disorder

Medical Professionals, Patient Organizations, Researchers, Regulatory, PDF, Other,

September 28, 2022

FDA’s Flexibility in Regulating Therapies